GlaxoSmithKline Pharmaceuticals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 45.6%)
- Efficient capital deployment (ROCE 61.4%)
- Virtually debt-free
- Regular dividends — yield 1.9%
Concerns
- High premium to book value (P/B 16.4x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
GLAXO · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII | 2.93% | 3.48% | 4.02% | 4.36% | 4.50% | 4.52% |
| DII | 8.64% | 7.90% | 7.51% | 7.34% | 7.30% | 7.79% |
| Public | 13.42% | 13.62% | 13.48% | 13.30% | 13.21% | 12.69% |
| Govt | 0.01% | — | — | — | — | — |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 57 Per Share
Dividend - Rs 42 Per Share
Interim Dividend - Rs 12 Per Share
Dividend - Rs 32 Per Share
Dividend - Rs 32 Per Share
Latest News
All newsAurobindo's Lannett launches generic Advair Diskus in US
*Aurobindo's Lannett launches generic Advair Diskus in US* — Lannett Company LLC, a wholly-owned subsidiary of Aurobindo Pharma, has launched a generic version of Advair Diskus® in the United States. The product is indicated for asthma and COPD, competing with GlaxoSmithKline’s branded drug. This launch expands Aurobindo’s presence in the US respiratory market. 📊 *STOCKS:* $AUROPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
GSK Pharma issues corrigendum to postal ballot notice
*GSK Pharma issues corrigendum to postal ballot notice dated August 3, 2026.* This is a procedural update correcting earlier communication related to shareholder voting. No financial or operational impact is indicated. Such filings are routine compliance requirements. 📊 *STOCKS:* $GSKPHARMA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
GSK Pharma hosts analyst call with no major announcements.
*GSK Pharma hosts analyst call with no major announcements.* The company shared updates during its recent investor meet, though no significant financial or operational changes were disclosed. Recording of the call is available on the NSE portal. Details remain largely informational with no immediate market-moving data. 📊 *STOCKS:* $GLAXO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnalystCall
GlaxoSmithKline Pharma shares unchanged on annual report update
*GlaxoSmithKline Pharma shares unchanged on annual report update.* The company shared a letter with the weblink to its annual report as part of a routine corporate filing. No financial or operational updates were disclosed. This is a standard disclosure with no immediate market impact. 📊 *STOCKS:* GSKPHARMA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnnualReport
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹995 Cr 4.4% | ₹1.0K Cr 6.2% | ₹980 Cr 21.7% | ₹805 Cr 17.4% | ₹974 Cr 2.6% | ₹949 Cr 6.1% | ₹1.0K Cr 24.0% | ₹815 Cr |
| Op. Profit | ₹351 Cr 5.4% | ₹371 Cr 10.4% | ₹336 Cr 33.9% | ₹251 Cr 24.6% | ₹333 Cr 14.0% | ₹292 Cr 9.3% | ₹322 Cr 39.4% | ₹231 Cr |
| OPM | 35.0% 2.8% | 36.0% 5.9% | 34.0% 9.7% | 31.0% 8.8% | 34.0% 9.7% | 31.0% 3.1% | 32.0% 14.3% | 28.0% |
| Net Profit | ₹278 Cr 6.1% | ₹296 Cr 15.2% | ₹257 Cr 25.4% | ₹205 Cr 22.1% | ₹263 Cr 14.3% | ₹230 Cr 8.7% | ₹252 Cr 38.5% | ₹182 Cr |
| EPS (₹) | 16.4 6.0% | 17.45 14.8% | 15.2 25.6% | 12.1 22.0% | 15.52 14.4% | 13.57 9.0% | 14.91 38.6% | 10.76 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.8K Cr 1.9% | ₹3.7K Cr 8.5% | ₹3.5K Cr 6.2% | ₹3.3K Cr 0.8% | ₹3.3K Cr 12.0% | ₹2.9K Cr 9.2% | ₹3.2K Cr 3.1% | ₹3.1K Cr 9.0% | ₹2.9K Cr 1.3% | ₹2.9K Cr |
| Expenses | ₹2.5K Cr 2.3% | ₹2.6K Cr 1.0% | ₹2.5K Cr 4.0% | ₹2.4K Cr 2.7% | ₹2.5K Cr 8.1% | ₹2.3K Cr 9.3% | ₹2.6K Cr 1.6% | ₹2.5K Cr 6.9% | ₹2.4K Cr 5.1% | ₹2.5K Cr |
| Op. Profit | ₹1.3K Cr 11.0% | ₹1.2K Cr 29.7% | ₹909 Cr 13.1% | ₹804 Cr 5.5% | ₹762 Cr 27.4% | ₹598 Cr 9.0% | ₹657 Cr 9.3% | ₹601 Cr 18.3% | ₹508 Cr 21.0% | ₹420 Cr |
| OPM | 34.0% 9.7% | 31.0% 19.2% | 26.0% 4.0% | 25.0% 8.7% | 23.0% 15.0% | 20.0% 0.0% | 20.0% 5.3% | 19.0% 5.6% | 18.0% 28.6% | 14.0% |
| Other Income | ₹166 Cr 11.4% | ₹149 Cr 809.5% | ₹-21 Cr 120.4% | ₹103 Cr 92.6% | ₹1.4K Cr 15466.7% | ₹9 Cr 103.4% | ₹-262 Cr 300.0% | ₹131 Cr 87.1% | ₹70 Cr 41.2% | ₹119 Cr |
| Interest | ₹3 Cr 200.0% | ₹1 Cr 50.0% | ₹2 Cr 0.0% | ₹2 Cr 0.0% | ₹2 Cr 50.0% | ₹4 Cr 33.3% | ₹6 Cr 500.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹66 Cr 1.5% | ₹67 Cr 4.3% | ₹70 Cr 6.1% | ₹66 Cr 2.9% | ₹68 Cr 13.9% | ₹79 Cr 4.8% | ₹83 Cr 69.4% | ₹49 Cr 28.9% | ₹38 Cr 40.7% | ₹27 Cr |
| PBT | ₹1.4K Cr 11.6% | ₹1.3K Cr 54.4% | ₹816 Cr 2.7% | ₹839 Cr 59.9% | ₹2.1K Cr 298.7% | ₹525 Cr 71.6% | ₹306 Cr 55.2% | ₹683 Cr 26.5% | ₹540 Cr 5.7% | ₹511 Cr |
| Tax % | 26.0% 0.0% | 26.0% 7.1% | 28.0% 3.7% | 27.0% 42.1% | 19.0% 40.6% | 32.0% 54.3% | 70.0% 100.0% | 35.0% 0.0% | 35.0% 2.9% | 34.0% |
| Net Profit | ₹1.0K Cr 11.6% | ₹928 Cr 57.3% | ₹590 Cr 3.4% | ₹611 Cr 64.0% | ₹1.7K Cr 373.5% | ₹358 Cr 284.9% | ₹93 Cr 79.1% | ₹445 Cr 26.8% | ₹351 Cr 4.2% | ₹337 Cr |
| EPS (₹) | 61.15 11.7% | 54.75 57.2% | 34.83 3.4% | 36.05 64.0% | 100.04 373.2% | 21.14 284.4% | 5.5 79.1% | 26.29 27.0% | 20.7 4.1% | 19.88 |
| Div Payout | 93.0% 6.1% | 99.0% 7.6% | 92.0% 3.4% | 89.0% 1.1% | 90.0% 36.6% | 142.0% 80.5% | 727.0% 856.6% | 76.0% 10.6% | 85.0% 13.3% | 75.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹169 Cr 0.0% | ₹169 Cr 0.0% | ₹169 Cr 0.0% | ₹169 Cr 0.0% | ₹169 Cr 0.0% | ₹169 Cr 0.0% | ₹169 Cr 0.0% | ₹169 Cr 98.8% | ₹85 Cr 0.0% | ₹85 Cr |
| Reserves | ₹2.1K Cr 17.7% | ₹1.8K Cr 10.8% | ₹1.6K Cr 2.3% | ₹1.6K Cr 37.0% | ₹2.5K Cr 90.5% | ₹1.3K Cr 20.7% | ₹1.7K Cr 16.2% | ₹2.0K Cr 0.2% | ₹2.0K Cr 2.7% | ₹1.9K Cr |
| Borrowings | ₹33 Cr 230.0% | ₹10 Cr 47.4% | ₹19 Cr 18.8% | ₹16 Cr 20.0% | ₹20 Cr 42.9% | ₹35 Cr | ₹0 Cr 100.0% | ₹1 Cr 0.0% | ₹1 Cr 50.0% | ₹2 Cr |
| Other Liabilities | ₹2.0K Cr 5.8% | ₹2.1K Cr 22.0% | ₹1.8K Cr 12.1% | ₹1.6K Cr 19.5% | ₹1.9K Cr 21.7% | ₹1.6K Cr 21.8% | ₹1.3K Cr 25.7% | ₹1.8K Cr 6.2% | ₹1.9K Cr 89.8% | ₹995 Cr |
| Total Liabilities | ₹4.3K Cr 5.3% | ₹4.1K Cr 15.5% | ₹3.6K Cr 6.9% | ₹3.3K Cr 28.2% | ₹4.6K Cr 48.7% | ₹3.1K Cr 0.7% | ₹3.1K Cr 19.8% | ₹3.9K Cr 0.9% | ₹3.9K Cr 31.4% | ₹3.0K Cr |
Assets | ||||||||||
| Fixed Assets | ₹281 Cr 1.1% | ₹284 Cr 11.5% | ₹321 Cr 2.7% | ₹330 Cr 0.3% | ₹331 Cr 14.5% | ₹387 Cr 48.9% | ₹758 Cr 75.5% | ₹432 Cr 32.9% | ₹325 Cr 26.0% | ₹258 Cr |
| CWIP | ₹33 Cr 135.7% | ₹14 Cr 0.0% | ₹14 Cr 30.0% | ₹20 Cr 33.3% | ₹30 Cr 130.8% | ₹13 Cr 89.2% | ₹120 Cr 88.0% | ₹1.0K Cr 8.7% | ₹923 Cr 52.6% | ₹605 Cr |
| Investments | ₹1.4K Cr 24.5% | ₹1.1K Cr 37.5% | ₹813 Cr 56.9% | ₹518 Cr 41.5% | ₹366 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹2.6K Cr 2.7% | ₹2.7K Cr 11.8% | ₹2.4K Cr 2.0% | ₹2.5K Cr 37.1% | ₹3.9K Cr 43.9% | ₹2.7K Cr 20.3% | ₹2.3K Cr 8.9% | ₹2.5K Cr 8.3% | ₹2.7K Cr 26.2% | ₹2.1K Cr |
| Total Assets | ₹4.3K Cr 5.3% | ₹4.1K Cr 15.5% | ₹3.6K Cr 6.9% | ₹3.3K Cr 28.2% | ₹4.6K Cr 48.7% | ₹3.1K Cr 0.7% | ₹3.1K Cr 19.8% | ₹3.9K Cr 0.9% | ₹3.9K Cr 31.4% | ₹3.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹903 Cr 30.0% | ₹1.3K Cr 121.6% | ₹582 Cr 20.2% | ₹484 Cr 40.3% | ₹811 Cr 40.3% | ₹578 Cr 18.0% | ₹490 Cr 19.8% | ₹409 Cr 13.5% | ₹473 Cr 102.1% | ₹234 Cr |
| Investing CF | ₹397 Cr 963.0% | ₹-46 Cr 611.1% | ₹9 Cr 98.9% | ₹808 Cr 299.0% | ₹-406 Cr 197.1% | ₹418 Cr 833.3% | ₹-57 Cr 62.7% | ₹-153 Cr 47.1% | ₹-104 Cr 134.6% | ₹301 Cr |
| Financing CF | ₹-737 Cr 4.2% | ₹-769 Cr 36.8% | ₹-562 Cr 63.6% | ₹-1.5K Cr 194.5% | ₹-524 Cr 24.7% | ₹-696 Cr 62.6% | ₹-428 Cr 19.6% | ₹-358 Cr 16.6% | ₹-307 Cr 39.9% | ₹-511 Cr |
| Net Cash Flow | ₹563 Cr 18.5% | ₹475 Cr 1537.9% | ₹29 Cr 111.6% | ₹-251 Cr 110.9% | ₹-119 Cr 139.7% | ₹300 Cr 4900.0% | ₹6 Cr 105.9% | ₹-102 Cr 264.5% | ₹62 Cr 158.3% | ₹24 Cr |
| Free Cash Flow | ₹870 Cr 31.7% | ₹1.3K Cr 122.2% | ₹573 Cr 27.1% | ₹451 Cr 81.0% | ₹2.4K Cr 342.4% | ₹536 Cr 59.5% | ₹336 Cr 102.4% | ₹166 Cr 74.0% | ₹639 Cr 2762.5% | ₹-24 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 26d 7.1% | 28d 21.7% | 23d 4.5% | 22d 4.3% | 23d 14.8% | 27d 145.5% | 11d 21.4% | 14d 26.3% | 19d 9.5% | 21d |
| Inventory Days | 124d 1.6% | 126d 12.5% | 144d 9.9% | 131d 9.0% | 144d 9.4% | 159d 17.8% | 135d 3.1% | 131d 10.9% | 147d 32.4% | 111d |
| Days Payable | 154d 17.2% | 186d 8.8% | 171d 40.2% | 122d 21.8% | 156d 15.6% | 135d 35.0% | 100d 8.3% | 109d 26.8% | 149d 104.1% | 73d |
| Cash Conv. Cycle | -4d 87.1% | -31d 675.0% | -4d 112.9% | 31d 181.8% | 11d 78.0% | 50d 8.7% | 46d 27.8% | 36d 111.8% | 17d 71.7% | 60d |
| Working Capital Days | -91d 8.1% | -99d 54.7% | -64d 12.3% | -57d 39.4% | -94d 141.0% | -39d 2.6% | -38d 47.2% | -72d 20.0% | -90d 1385.7% | 7d |
| ROCE | 61.0% 3.2% | 63.0% 23.5% | 51.0% 41.7% | 36.0% 2.7% | 37.0% 2.6% | 38.0% 15.2% | 33.0% 6.5% | 31.0% 19.2% | 26.0% 18.2% | 22.0% |
Source: Screener.in · Lower days = better efficiency
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
HealthcarePharmaceuticals & Biotechnology